October 31, 2025 — Leads & Copy — FibroBiologics, Inc. (Nasdaq: FBLG) announced its third-quarter 2025 financial results and provided a corporate update, advancing preparations to begin manufacturing its fibroblast-based spheroids product candidate, CYWC628, for the Phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers (DFU) patients. The company is also preparing to submit Investigational New Drug applications for treating psoriasis with CYPS317 and multiple sclerosis with CYMS101.
Recent highlights include positive IND-enabling updates from the psoriasis research program, advancing the Bone Marrow Organoid platform, filing a patent application for generating multipotent cells from fibroblasts, and publishing an article presenting the scientific case for fibroblast cells’ therapeutic advantages. Upcoming milestones include completing manufacturing training runs for CYWC628, completing the manufacturing of CYWC628 in accordance with FDA Good Manufacturing Practices (cGMP), initiating a Phase 1/2 clinical trial in Australia, completing pre-clinical IND-enabling studies for CYPS317 and CYMS101, and submitting INDs.
For the nine months ended September 30, 2025, research and development expenses were approximately $6.6 million, and general and administrative expenses were approximately $7.4 million, resulting in a net loss of approximately $15.4 million. Cash and cash equivalents totaled approximately $4.9 million at September 30, 2025.
Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics, noted that the company is efficiently moving its most advanced product candidates towards the clinic while demonstrating that fibroblasts can be a scalable platform.
Contact: Nic Johnson, Russo Partners, (212) 845-4242, fibrobiologicsIR@russopr.com; Liz Phillips, Russo Partners, (347) 956-7697, Elizabeth.phillips@russopartnersllc.com
Source: FibroBiologics
